Abstract
Nanoparticles occur naturally as part of repetitive molecular structures forming virus-like particles (VLPs). VLPs are powerful immune activators. Specifically, VLP can elicit a direct activation of B lymphocytes to trigger production of antibodies targeted at molecules chemically linked to the VLP. We here review recent data from genetics research, large-scale genomic sequencing, as well as clinical trials which suggest that a VLP-based vaccine against the signaling molecule IL-17 will be safe and effective in the common skin disease psoriasis, as well as other conditions. Active vaccination against IL-17 is capable of replacing the costly manufacture of antibodies currently in clinical use with huge implications for treatment availability and health economics.
Original language | English |
---|---|
Pages (from-to) | 1361-1369 |
Number of pages | 9 |
Journal | Nanomedicine |
Volume | 10 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- IL-17
- Psoriasis
- Vaccine
- Virus-like particle
ASJC Scopus subject areas
- General Materials Science
- Bioengineering
- Biomedical Engineering
- Medicine (miscellaneous)
- Development